direct/ Entelos: Entelos Announces Expanded Collaboration With Johnson & Johnson Pharmaceutical Research & Development

FOSTER CITY, CA -- (MARKET WIRE) -- 03/16/2006 -- Entelos, Inc., a leader in predictive biosimulation technologies for drug discovery, development, and commercialization, announced today that it has expanded its research collaboration with Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) to include multiple therapeutic areas over a five-year term. During the first year of this new agreement, Entelos will dedicate several teams of research engineers and life scientists to support specific projects using its PhysioLab® platforms on behalf of J&JPRD and its affiliates.

As previously reported, J&JPRD is already using Entelos´ models to validate targets, select biomarkers, and optimize clinical trials for type II diabetes, obesity, and anemia.

"Entelos is extremely pleased to expand its long-standing relationship with J&JPRD with this broadened collaboration," stated James Karis, President and CEO of Entelos. "From our earliest agreement signed in November 1999, J&JPRD and its affiliates recognized the value in accurately simulating human biology in silico (in a computer) to rapidly validate novel drug targets, discover biomarkers, and evaluate and develop new drugs. We believe J&JPRD´s continued commitment to apply the power of biosimulation to their drug discovery and development decisions will lead to safer and more effective medicines for patients."

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company that applies engineering principles and mathematical modeling approaches to simulate human biology. The company helps its pharmaceutical and biotechnology customers increase the efficiency of the drug discovery, development, and commercialization process by accurately predicting human response to therapeutic intervention. Entelos´ teams of life scientists and engineers use its proprietary computer platforms, called PhysioLab systems, to create "virtual patients" and apply them to validate early research theories, translate preclinical data into meaningful human results, and optimize clinical trial designs in diseases such as asthma, obesity, type I and type II diabetes, and rheumatoid arthritis. The company is also currently developing models in cardiovascular and skin sensitization, and intends to expand its modeling capability into a variety of disease areas including metabolic syndrome, chronic obstructive pulmonary disease, osteoporosis and Alzheimer´s.

Founded in 1996, and backed by multinational corporations and venture capitalists, including Pfizer, Hewlett Packard and Abingworth, Entelos has raised over US$50 million and currently has 80 employees. It has 12 issued patents and over 70 pending applications worldwide directed to its PhysioLab software platform, the PhysioLab models themselves, biological methods, and methodologies of applying its PhysioLab models to drug discovery and development. In addition to co-development and internal research programs, Entelos partners with pharmaceutical and biotechnology companies worldwide.

Entelos is a registered trademark of Entelos, Inc. PhysioLab is a registered trademark and service mark of Entelos, Inc.


Enquiries:

Entelos, Inc.
Jill Fujisaki
Vice President Strategic Alliances
Tel: +1 650 572 5430
fujisaki@entelos.com

Brunswick Group
Justine McIlroy
Alex Tweed
Jon Coles
Tel: +44 207404 5959

SOURCE: Entelos, Inc.




The announcement distributed by directnews.
The issuer is solely responsible for the content of this announcement.

This release was published on openPR.